We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sequencing Study Links Mutations in Major Heart Muscle Protein to Development of Dilated Cardiomyopathy

By LabMedica International staff writers
Posted on 26 Jan 2015
British heart disease researchers using advanced gene sequencing techniques have identified mutations in the TTN gene, which encodes the muscle protein titin, linked to development of dilated cardiomyopathy (DCM) that are different from benign mutations in this gene that are carried by a large percentage of the population.

In DCM a portion of the myocardium is dilated, often without any obvious cause. More...
Left or right ventricular systolic pump function of the heart is impaired, leading to progressive cardiac enlargement and hypertrophy, a process called remodeling. Dilated cardiomyopathy is the most common form of non-ischemic cardiomyopathy, and one in three cases of congestive heart failure (CHF) is due to dilated cardiomyopathy. It occurs more frequently in men than in women, and is most common between the ages of 20 and 60 years.

Titin, also known as connectin, is a giant protein that functions as a molecular spring which is responsible for the passive elasticity of muscle. It is composed of 244 individually folded protein domains connected by unstructured peptide sequences. These domains unfold when the protein is stretched and refold when the tension is removed. With its length of from about 27,000 to 33,000 amino acids (depending on the splice isoform), titin is the largest known protein, and the TTN gene contains the largest number of exons (363) discovered in any single gene.

The recent discovery of heterozygous human mutations that truncate full-length titin promises new prospects for improving heart failure management. However, realization of this opportunity has been hindered by the large number of TTN-truncating variants (TTNtv) in the general population and uncertainty about their consequences in health or disease.

In order to distinguish between TTN mutations linked to DCM and benign mutations in this gene, investigators at Imperial College London (United Kingdom) coupled TTN gene sequencing with cardiac phenotyping in 5267 individuals across the spectrum of cardiac physiology and integrated these data with RNA and protein analyses of human heart tissues.

They found diversity of TTN isoform expression in the heart, defined the relative inclusion of TTN exons in different isoforms, and demonstrated that these data, coupled with the position of the TTNtv, provided a robust strategy to discriminate pathogenic from benign TTNtv. They showed that TTNtv was the most common genetic cause of DCM in ambulant patients in the community, identified clinically important manifestations of TTNtv-positive DCM, and defined the penetrance and outcomes of TTNtv in the general population. The key finding was that TTN mutations in healthy individuals usually occurred in regions of the gene that were not included in the final protein, allowing titin to remain functional.

Senior author Dr. Stuart Cook, professor of clinical and molecular cardiology at Imperial College London, said, "These results give us a detailed understanding of the molecular basis for dilated cardiomyopathy. We can use this information to screen patients' relatives to identify those at risk of developing the disease, and help them to manage their condition early."

The study was published in the January 14, 2014, online edition of the journal Science Translational Medicine.

Related Links:
Imperial College London



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.